Research programme: anticancer vinca alkaloid analogues - AMRI
Latest Information Update: 09 Feb 2009
At a glance
- Originator AMRI
- Mechanism of Action Tubulin polymerisation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 02 May 2007 Albany Molecular Research is now called AMRI
- 13 Feb 2007 Preclinical trials in Solid tumours in USA (unspecified route)